Top

Published in:

Open Access 01-12-2019 | Melanoma | Practical Approach

Management Issues in Conjunctival Tumours: Conjunctival Melanoma and Primary Acquired Melanosis

Authors: Victoria M. L. Cohen, Roderick F. O’Day

Published in: Ophthalmology and Therapy | Issue 4/2019

Abstract

Conjunctival melanoma is a rare malignant condition of the ocular surface. It is potentially lethal, with regional lymph node spread often preceding distant solid-organ metastasis. Due to its rarity and the long latency between treatment and local recurrence or the development of metastases, it is difficult to study. The literature is composed entirely of case series of varying quality, and there is significant variability in the management of this condition. This commentary attempts to distil the evidence base to provide practical management tips for the clinician.

Shields CL, Alset AE, Boal NS, et al. Conjunctival tumors in 5002 cases. Comparative analysis of benign versus malignant counterparts. The 2016 James D. Allen lecture. Am J Ophthalmol. 2017;173:106–33. https://doi.org/10.1016/j.ajo.2016.09.034.CrossRefPubMed

Triay E, Bergman L, Nilsson B, All-Ericsson C, Seregard S. Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol. 2009;93(11):1524–8. https://doi.org/10.1136/bjo.2009.157933.CrossRefPubMed

Tuomaala S, Eskelin S, Tarkkanen A, Kivelä T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43(11):3399–408.PubMed

Yu G-P, Hu D-N, McCormick S, Finger PT. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol. 2003;135(6):800–6.CrossRefPubMed

De Potter P, Shields CL, Shields JA, Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol. 1993;77(10):624–30. https://doi.org/10.1136/bjo.77.10.624.CrossRefPubMedPubMedCentral

Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118(2):389–95. https://doi.org/10.1016/j.ophtha.2010.06.021(e1-2).CrossRefPubMed

Paridaens AD, McCartney AC, Hungerford JL. Multifocal amelanotic conjunctival melanoma and acquired melanosis sine pigmento. Br J Ophthalmol. 1992;76(3):163–5. https://doi.org/10.1136/bjo.76.3.163.CrossRefPubMedPubMedCentral

Werschnik C, Lommatzsch PK. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol. 2002;25(3):248–55.CrossRefPubMed

Folberg R, McLean IW, Zimmerman LE. Primary acquired melanosis of the conjunctiva. Hum Pathol. 1985;16(2):129–35. https://doi.org/10.1016/s0046-8177(85)80061-7.CrossRefPubMed

10.

Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Surv Ophthalmol. 2004;49(1):3–24.CrossRefPubMed

11.

Ackerman AB, Sood R, Koenig M. Primary acquired melanosis of the conjunctiva is melanoma in situ. Mod Pathol. 1991;4(2):253–63.PubMed

12.

Damato B, Coupland SE. Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. Clin Experiment Ophthalmol. 2008;36(8):786–95. https://doi.org/10.1111/j.1442-9071.2008.01888.x.CrossRefPubMed

13.

Shields JA, Shields CL, Mashayekhi A, et al. Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture. Ophthalmology. 2008;115(3):511.e2–519.e2. https://doi.org/10.1016/j.ophtha.2007.07.003.CrossRef

14.

Jakobiec FA, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology. 1989;96(2):147–66. https://doi.org/10.1016/s0161-6420(89)32920-4.CrossRefPubMed

15.

Seregard S. Conjunctival melanoma. Surv Ophthalmol. 1998;42(4):321–50.CrossRefPubMed

16.

Folberg R, McLean IW. Primary acquired melanosis and melanoma of the conjunctiva: terminology, classification, and biologic behavior. Hum Pathol. 1986;17(7):652–4. https://doi.org/10.1016/s0046-8177(86)80175-7.CrossRefPubMed

17.

Oellers P, Karp CL. Management of pigmented conjunctival lesions. Ocul Surf. 2012;10(4):251–63. https://doi.org/10.1016/j.jtos.2012.08.002.CrossRefPubMed

18.

Jakobiec FA, Rini FJ, Fraunfelder FT, Brownstein S. Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma. Experience with 62 cases. Ophthalmology. 1988;95(8):1058–70. https://doi.org/10.1016/s0161-6420(88)33058-7.CrossRefPubMed

19.

Gloor P, Alexandrakis G. Clinical characterization of primary acquired melanosis. Gaz Med Fr. 1995;36(8):1721–9.PubMed

20.

Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2005;243(11):1108–14. https://doi.org/10.1007/s00417-004-1080-y.CrossRef

21.

Pe’er J, Frucht-Pery J. The treatment of primary acquired melanosis (PAM) with atypia by topical mitomycin C. Am J Ophthalmol. 2005;139(2):229–34. https://doi.org/10.1016/j.ajo.2004.08.065.CrossRefPubMed

22.

Chalasani R, Giblin M, Conway RM. Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment. Clin Experiment Ophthalmol. 2006;34(7):708–14. https://doi.org/10.1111/j.1442-9071.2006.01356.x.CrossRefPubMed

23.

Esmaeli B, Wang X, Youssef A, Gershenwald JE. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology. 2001;108(11):2101–5.CrossRefPubMed

24.

Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol Chic Ill 1960. 2005;123(12):1639–43. https://doi.org/10.1001/archopht.123.12.1639.CrossRef

25.

Larsen A-C, Dahmcke CM, Dahl C, et al. A retrospective review of conjunctival melanoma presentation, treatment, and outcome and an investigation of features associated with BRAF mutations. JAMA Ophthalmol. 2015;133(11):1295–303. https://doi.org/10.1001/jamaophthalmol.2015.3200.CrossRefPubMed

26.

Larsen A-C, Dahl C, Dahmcke CM, et al. BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions. Acta Ophthalmol (Copenh). 2016;94(5):463–70. https://doi.org/10.1111/aos.13007.CrossRef

27.

Missotten GS, de Wolff-Rouendaal D, de Keizer RJW. Screening for conjunctival melanoma metastasis: literature review. Bull Soc Belge Ophtalmol. 2007;306:23–30.

28.

Jakobiec FA. Conjunctival melanoma. Arch Ophthalmol Chic Ill 1960. 1981;99(3):513–6. https://doi.org/10.1001/archopht.1981.03930010514031.CrossRef

29.

Lommatzsch PK, Lommatzsch RE, Kirsch I, Fuhrmann P. Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol. 1990;74(10):615–9. https://doi.org/10.1136/bjo.74.10.615.CrossRefPubMedPubMedCentral

30.

Damato B, Coupland SE. An audit of conjunctival melanoma treatment in Liverpool. Eye Lond Engl. 2009;23(4):801–9. https://doi.org/10.1038/eye.2008.154.CrossRef

31.

Paridaens AD, Minassian DC, McCartney AC, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol. 1994;78(4):252–9. https://doi.org/10.1136/bjo.78.4.252.CrossRefPubMedPubMedCentral

32.

Shields CL. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc. 2000;98:471–92.PubMedPubMedCentral

33.

Shields JA, Shields CL, De Potter P. Surgical management of circumscribed conjunctival melanomas. Ophthal Plast Reconstr Surg. 1998;14(3):208–15.CrossRefPubMed

34.

Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture. Arch Ophthalmol Chic Ill 1960. 1997;115(6):808–15.CrossRef

35.

Brouwer NJ, Marinkovic M, van Duinen SG, Bleeker JC, Jager MJ, Luyten GPM. Treatment of conjunctival melanoma in a Dutch referral centre. Br J Ophthalmol. 2018;102(9):1277–82. https://doi.org/10.1136/bjophthalmol-2017-311082.CrossRefPubMed

36.

Karim R, Conway RM. Conservative resection and adjuvant plaque brachytherapy for early-stage conjunctival melanoma. Clin Experiment Ophthalmol. 2011;39(4):293–8. https://doi.org/10.1111/j.1442-9071.2010.02469.x.CrossRefPubMed

37.

Treacher Collins E. Case of epibulbar sarcoma cured by its removal and the application of radium. Trans Ophthal Soc UK. 1918;38:125–7.

38.

Cohen VML, Papastefanou VP, Liu S, Stoker I, Hungerford JL. The use of strontium-90 beta radiotherapy as adjuvant treatment for conjunctival melanoma. J Oncol. 2013;2013:349162. https://doi.org/10.1155/2013/349162.CrossRefPubMedPubMedCentral

39.

Lederman M, Wybar K, Busby E. Malignant epibulbar melanoma: natural history and treatment by radiotherapy. Br J Ophthalmol. 1984;68(9):605–17. https://doi.org/10.1136/bjo.68.9.605.CrossRefPubMedPubMedCentral

40.

Zografos L, Uffer S, Bercher L, Gailloud C. Combined surgery, cryocoagulation and radiotherapy for treatment of melanoma of the conjunctiva. Klin Monatsbl Augenheilkd. 1994;204(5):385–90. https://doi.org/10.1055/s-2008-1035564.CrossRefPubMed

41.

Stannard CE, Sealy GR, Hering ER, Pereira SB, Knowles R, Hill JC. Malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy. Ophthalmology. 2000;107(5):951–8. https://doi.org/10.1016/s0161-6420(00)00061-0.CrossRefPubMed

42.

Desjardins L, Poncet P, Levy C, Schlienger P, Asselain B, Validire P. Prognostic factors in malignant melanoma of the conjunctiva. An anatomo-clinical study of 56 patients. J Fr Ophtalmol. 1999;22(3):315–21.PubMed

43.

Walsh-Conway N, Conway RM. Plaque brachytherapy for the management of ocular surface malignancies with corneoscleral invasion. Clin Experiment Ophthalmol. 2009;37(6):577–83. https://doi.org/10.1111/j.1442-9071.2009.02092.x.CrossRefPubMed

44.

Wong JR, Nanji AA, Galor A, Karp CL. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014;9(3):185–204. https://doi.org/10.1586/17469899.2014.921119.CrossRefPubMedPubMedCentral

45.

Fernandes BF, Nikolitch K, Coates J, et al. Local chemotherapeutic agents for the treatment of ocular malignancies. Surv Ophthalmol. 2014;59(1):97–114. https://doi.org/10.1016/j.survophthal.2013.01.003.CrossRefPubMed

46.

Benage MJ, Morrow NC, Janson BJ, Greiner MA. Evaluation of interferon alpha 2b as adjunctive therapy for conjunctival melanoma. Am J Ophthalmol Case Rep. 2019. https://doi.org/10.1016/j.ajoc.2019.100467.CrossRefPubMedPubMedCentral

47.

Kikuchi I, Kase S, Ishijima K, Ishida S. Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2017;255(11):2271–6. https://doi.org/10.1007/s00417-017-3754-2.CrossRef

48.

Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol. 2008;145(1):124–9. https://doi.org/10.1016/j.ajo.2007.08.027.CrossRefPubMed

49.

Ditta LC, Shildkrot Y, Wilson MW. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ophthalmology. 2011;118(9):1754–9. https://doi.org/10.1016/j.ophtha.2011.01.060.CrossRefPubMed

50.

Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol. 1998;82(5):476–9. https://doi.org/10.1136/bjo.82.5.476.CrossRefPubMedPubMedCentral

51.

Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol Chic Ill 1960. 2000;118(7):885–91.

52.

Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol. 2006;90(7):819–22. https://doi.org/10.1136/bjo.2005.086850.CrossRefPubMedPubMedCentral

53.

Mendoza PR, Grossniklaus HE. Sentinel lymph node biopsy for eyelid and conjunctival tumors: what is the evidence? Int Ophthalmol Clin. 2015;55(1):123–36. https://doi.org/10.1097/IIO.0000000000000051.CrossRefPubMedPubMedCentral

54.

Savar A, Ross MI, Prieto VG, Ivan D, Kim S, Esmaeli B. Sentinel lymph node biopsy for ocular adnexal melanoma: experience in 30 patients. Ophthalmology. 2009;116(11):2217–23. https://doi.org/10.1016/j.ophtha.2009.04.012.CrossRefPubMed

55.

Cohen VML, Tsimpida M, Hungerford JL, Jan H, Cerio R, Moir G. Prospective study of sentinel lymph node biopsy for conjunctival melanoma. Br J Ophthalmol. 2013;97(12):1525–9. https://doi.org/10.1136/bjophthalmol-2013-303671.CrossRefPubMed

56.

Pfeiffer ML, Ozgur OK, Myers JN, et al. Sentinel lymph node biopsy for ocular adnexal melanoma. Acta Ophthalmol (Copenh). 2017;95(4):e323–8. https://doi.org/10.1111/aos.13252.CrossRef

57.

Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609. https://doi.org/10.1056/NEJMoa1310460.CrossRefPubMedPubMedCentral

58.

Vora GK, Demirci H, Marr B, Mruthyunjaya P. Advances in the management of conjunctival melanoma. Surv Ophthalmol. 2017;62(1):26–42. https://doi.org/10.1016/j.survophthal.2016.06.001.CrossRefPubMed

59.

Spendlove HE, Damato BE, Humphreys J, Barker KT, Hiscott PS, Houlston RS. BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res. 2004;14(6):449–52.CrossRefPubMed

60.

Gear H, Williams H, Kemp EG, Roberts F. BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci. 2004;45(8):2484–8. https://doi.org/10.1167/iovs.04-0093.CrossRefPubMed

61.

Goldenberg-Cohen N, Cohen Y, Rosenbaum E, et al. T1799A BRAF mutations in conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci. 2005;46(9):3027–30. https://doi.org/10.1167/iovs.04-1449.CrossRefPubMed

62.

Griewank KG, Westekemper H, Murali R, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res. 2013;19(12):3143–52. https://doi.org/10.1158/1078-0432.CCR-13-0163.CrossRefPubMed

63.

Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239–46. https://doi.org/10.1200/JCO.2010.32.4327.CrossRefPubMed

64.

Broman KK, Dossett LA, Sun J, Eroglu Z, Zager JS. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opin Drug Saf. 2019;18(5):381–92. https://doi.org/10.1080/14740338.2019.1607289.CrossRefPubMed

65.

Rossi E, Maiorano BA, Pagliara MM, et al. Dabrafenib and trametinib in BRAF mutant metastatic conjunctival melanoma. Front Oncol. 2019;9:232. https://doi.org/10.3389/fonc.2019.00232.CrossRefPubMedPubMedCentral

66.

Pinto Torres S, André T, Gouveia E, Costa L, Passos MJ. Systemic treatment of metastatic conjunctival melanoma. Case Rep Oncol Med. 2017;2017:4623964. https://doi.org/10.1155/2017/4623964.CrossRefPubMedPubMedCentral

67.

Mor JM, Heindl LM. Systemic BRAF/MEK inhibitors as a potential treatment option in metastatic conjunctival melanoma. Ocul Oncol Pathol. 2017;3(2):133–41. https://doi.org/10.1159/000452473.CrossRefPubMed

68.

Finger PT, Pavlick AC. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series. J Immunother Cancer. 2019;7(1):83. https://doi.org/10.1186/s40425-019-0555-7.CrossRefPubMedPubMedCentral

69.

Sagiv O, Thakar SD, Kandl TJ, et al. Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma. JAMA Ophthalmol. 2018;136(11):1236–41. https://doi.org/10.1001/jamaophthalmol.2018.3488.CrossRefPubMedPubMedCentral

Title: Management Issues in Conjunctival Tumours: Conjunctival Melanoma and Primary Acquired Melanosis
Authors: Victoria M. L. Cohen
Roderick F. O’Day
Publication date: 01-12-2019
Publisher: Springer Healthcare
Keywords: Melanoma
Melanoma
Cryotherapy
Cryotherapy
Radiotherapy
Cytostatic Therapy
Published in: Ophthalmology and Therapy / Issue 4/2019
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI: https://doi.org/10.1007/s40123-019-00219-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Management Issues in Conjunctival Tumours: Conjunctival Melanoma and Primary Acquired Melanosis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

One-Year Outcomes of Second-Generation Trabecular Micro-Bypass Stents (iStent Inject) Implantation with Cataract Surgery in Different Glaucoma Subtypes and Severities

Atropine 0.01% Eye Drops for Myopia Control in American Children: A Multiethnic Sample Across Three US Sites

Influence of Postoperative Posture on Macular Slippage after Macula-Off Retinal Detachment: A Randomized Controlled Trial

Optical Coherence Tomography-Based Deep-Learning Models for Classifying Normal and Age-Related Macular Degeneration and Exudative and Non-Exudative Age-Related Macular Degeneration Changes

Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration

Association of the Robert Wood Johnson Foundations’ Social Determinants of Health and Medicare Ocular Hospitalizations: A Cross Sectional Data Analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page